FRM
DCPH

Fox Run Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Fox Run Management’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,399
Closed -$168K – 1130
2023
Q4 		$168K Sell
10,399
-12,141
-54% -$155K 0.04% 654
2023
Q3 		$287K Buy
+22,540
New +$311K 0.08% 463
2023
Q2 		– Sell
-25,248
Closed -$390K – 1027
2023
Q1 		$390K Buy
+25,248
New +$422K 0.13% 310
2022
Q4 		– Sell
-24,300
Closed -$450K – 943
2022
Q3 		$450K Buy
24,300
+13,874
+133% +$218K 0.18% 211
2022
Q2 		$137K Buy
+10,426
New +$115K 0.07% 451

Other funds holding DCPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Fox Run Management's DCPH Position: Q1 2024 in Review

Fox Run Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2024, closing a stake of 10,399 shares — an estimated $168K sold.

Fox Run Management first reported a position in DCPH in Q2 2022 and held it in 5 quarters. The position peaked at $450K in Q3 2022. 177 funds tracked by Wall St. Rank hold DCPH as of Q1 2024.

  • Fox Run Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Fox Run Management sold 10,399 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $168K.
  • Fox Run Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • Fox Run Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $450K in Q3 2022.
  • 177 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Fox Run Management's 13F filing for Q1 2024, filed 13 May 2024.